Matsumoto M, Aranami A, Ishige A, Watanabe K, Benno Y
Dairy Science and Technology Institute, Kyodo Milk Industry Co. Ltd., Hinode-cho, Tokyo, Japan.
Clin Exp Allergy. 2007 Mar;37(3):358-70. doi: 10.1111/j.1365-2222.2007.02642.x.
In atopic dermatitis (AD) patients, the intestinal mucosal barrier function is weakened, permiting frequent invasion by antigens. Polyamines and short-chain fatty acids (SCFA) produced by intestinal bacteria are involved in the promotion of intestinal mucosal barrier functions.
Our aim was to investigate the effect of pro-biotic yogurt containing Bifidobacterium animalis subsp. lactis LKM512 (LKM512 yogurt) on subjective symptoms, intestinal microbiota, intestinal bacterial metabolites (polyamines and SCFA), and T-helper type 1 (Th1)/Th2 balance in intractable AD patients.
In a double-blind, placebo-controlled, crossover study, LKM512 yogurt was given for 4 weeks to 10 adult AD patients who were diagnosed with moderate AD (four males and six females; average age, 22.1 years). The subjective symptoms were recorded after each intervention. The dynamics of fecal microbiota were analysed by the terminal-restriction fragment length polymorphism method. The effects of LKM512 yogurt on fecal polyamines, SCFA, and serum cytokines were evaluated.
Scores of itch and burning tended to improve to a greater extent by LKM512 yogurt consumption than by placebo consumption. LKM512 yogurt (P<0.005) and placebo consumption (P<0.05) significantly increased the serum IFN-gamma concentration by six- and threefold, respectively. Fecal microbiota was altered dynamically by LKM512 yogurt consumption, in particular, the bacterial species and phylotypes of Bifidobacterium, Clostridium cluster IV and subcluster XIVa were increased in number. In addition, fecal spermidine concentration was significantly (P<0.05) increased, while fecal butyrate also tended to be increased by LKM512 yogurt consumption.
We conclude that LKM512 yogurt consumption may be effective against intractable adult-type AD and this effect depends on the recovery of the intestinal mucosal barrier function and the induction of the Th1-type cytokine by polyamines and SCFA, particularly, butyrate, produced by the altered intestinal microbiota.
在特应性皮炎（AD）患者中，肠道黏膜屏障功能减弱，使得抗原频繁侵入。肠道细菌产生的多胺和短链脂肪酸（SCFA）参与促进肠道黏膜屏障功能。
我们的目的是研究含有动物双歧杆菌乳酸亚种LKM512的益生菌酸奶（LKM512酸奶）对难治性AD患者的主观症状、肠道微生物群、肠道细菌代谢产物（多胺和SCFA）以及1型辅助性T细胞（Th1）/Th2平衡的影响。
在一项双盲、安慰剂对照、交叉研究中，将LKM512酸奶给予10名被诊断为中度AD的成年患者（4名男性和6名女性；平均年龄22.1岁），为期4周。每次干预后记录主观症状。通过末端限制性片段长度多态性方法分析粪便微生物群的动态变化。评估LKM512酸奶对粪便多胺、SCFA和血清细胞因子的影响。
与食用安慰剂相比，食用LKM512酸奶后瘙痒和灼痛评分改善程度更大。LKM512酸奶（P<0.005）和食用安慰剂（P<0.05）分别使血清干扰素-γ浓度显著升高6倍和3倍。食用LKM512酸奶可动态改变粪便微生物群，特别是双歧杆菌、梭菌属IV群和 XIVa亚群的细菌种类和系统型数量增加。此外，LKM512酸奶使粪便亚精胺浓度显著升高（P<0.05），同时粪便丁酸盐也有升高趋势。
我们得出结论，食用LKM512酸奶可能对难治性成人型AD有效，这种效果取决于肠道黏膜屏障功能的恢复以及多胺和SCFA（特别是由改变的肠道微生物群产生的丁酸盐）对Th1型细胞因子的诱导。
